Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding Study of Selinexor in Relapsed/Refractory Multiple Myeloma Patients with Impaired Renal Function
KCT0008434Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- May 2023
- Countries
- 1
- Sponsor
- Seoul St. Mary's Hospital
- Modality
- Small Molecules
- Drugs
- selinexor
- Conditions
- multiple myeloma (MM)
01
Overview
Phase 2 trial of selinexor in multiple myeloma (MM), sponsored by Seoul St. Mary's Hospital. Planned start May 2023; status: not yet recruiting.
02
Design
- Study design
- Non-randomizedSingle group
03
Who it enrols
Adult patients with relapsed and/or refractory multiple myeloma and impaired renal function; healthy volunteers are not included.
Beyond the preview
Go deeper on KCT0008434.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008434.